Best practices for pediatric liver MRI: guidelines from members of the Society for Pediatric Radiology Magnetic Resonance and Abdominal Imaging Committees
- Open Access
- 10.09.2025
- Guideline
Abstract
Introduction
Field strength considerations
Specialized imaging equipment
Gadolinium-based contrast agents
Contrast agent | Trade name | Type | T1 relaxivity in human plasma at 37 °C mM−1 s−1 | T2 relaxivity in human plasma at 37 ℃, LmM−1 s−1 | Clearance | ACR classification | FDA-approved ages |
|---|---|---|---|---|---|---|---|
(1.5 T/3 T)* | (1.5 T/3 T) | ||||||
Gadodiamide | Omniscan | Linear | 4.3/4.0 | 5.2/5.6 | Renal | Group I | ≥ 2 years |
Non-ionic | |||||||
Gadopentetate dimeglumine | Magnevist | Linear | 4.1/3.7 | 4.6/5.2 | Renal | Group I | ≥ 2 years |
Non-ionic | |||||||
Gadobenate dimeglumine | MultiHance | Linear | 6.3/5.5 | 8.7/11.0 | Renal (95–96%) and hepatobiliary (4–5%) | Group II | All ages |
Non-ionic | |||||||
Gadobutrol | Gadavist/ Gadovist | Macrocyclic non-ionic | 5.2/5.0 | 6.1/7.1 | Renal | Group II | All ages |
Gadoteric acid | Dotarem | Macrocyclic ionic | 3.6/3/5 | 4.3/4.9 | Renal | Group II | All ages |
Gadoteridol | ProHance | Macrocyclic non-ionic | 4.1/3.7 | 5.0/5.7 | Renal | Group II | All ages |
Gadoxetate disodium | Eovist/ | Linear | 6.9/6.2 | 8.7/11.0 | Hepatobiliary (50%) and renal (50%) | Group III | All ages |
Primovist | Ionic | ||||||
Gadopiclenol | Vueway/Elucirem | Macrocyclic non-ionic | 19/9.9 | 34/60 | Renal | Group II | ≥ 2 years |
Motion management
Patient comfort and preparation
Motion mitigation sequences and strategies
Rapid imaging and acceleration sequences and strategies
Respiratory synchronization
Age-specific protocol optimization
Age | Motion management | Axial FOV (mm) | Coronal FOV (mm) |
|---|---|---|---|
Infant/neonate (< 6 months) | Free-breathing. Feed and bundle up to 6 months | 200 | 220 |
Toddler (6 months–6 years) | Free-breathing. Usually sedated | 250 | 280 |
School-aged (> 6 years) | Non-sedated free-breathing exams are possible in some children | 300 | 320 |
Teenager | Breath-hold coaching with motion mitigation | 330 | 340 |
General techniques
Liver anatomy and general parenchymal evaluation |
|---|
Axial T2 FS (optional axial T2 non-FS, optional coronal T2) |
Axial T1 in/opposed-phase or Dixon (IP/OP/F/W) |
Optional: axial 2D bSSFP |
Optional: axial T1 FS post-contrast |
Additional sequences for liver mass |
Axial DWI (B = 50, 800 s/mm2) |
Axial T1 FS pre-contrast |
Axial T1 FS dynamic post-contrast (30 s, 60 s, 3 min) |
Coronal T1 FS post-contrast (3 min) |
Additional sequences for biliary imaging |
Coronal 2D thick slab T2 SS-FSE MRCP |
Coronal 3D T2 MRCP |
Axial/coronal T1 FS hepatobiliary-phase contrast-enhanced MRCP |
Additional sequences for quantitative evaluation |
Iron quantification: R2*/R2 |
Fat quantification: PDFF |
Stiffness quantification: MR elastography |
Additional sequences for vascular imaging |
3D spoiled GRE (post-contrast MRA): GBCA |
3D spoiled GRE (post-contrast MRA): ferumoxytol |
Time-resolved MRA |
Liver anatomy and general parenchymal evaluation
Liver mass
Hepatobiliary contrast for liver mass | ||
|---|---|---|
Mandatory sequences | Performance notes | Utility |
Dynamic post-contrast | ||
Axial T1 FS 3D GRE – Late Arterial | 16–20 s after injection | Assessment of arterial phase enhancement characteristics; assessment of hepatic artery. Note: For late arterial phase contrast should be present in the portal venous system, but not the hepatic veins |
Axial T1 FS 3D GRE – Portal Venous | 45–60 s after injection | Assessment of portal venous phase enhancement characteristics; assessment of portal vein |
Axial T1 FS 3D GRE – Transitional | 2–5 min after injection | Assessment of transitional phase enhancement characteristics; assessment of hepatic veins |
Axial T1 FS 3D GRE – Hepatobiliary | 15–20 min (gadoxetate) 45–60 min (gadobenate) | Assessment of hepatobiliary phase enhancement characteristics and retention or lack thereof of the contrast agent; assessment of the biliary tree |
Coronal T1 FS 3D GRE – Hepatobiliary | Optional; 15–20 min | Assessment of hepatobiliary phase enhancement characteristics and retention or lack thereof of the contrast agent; assessment of the biliary tree |
Extracellular contrast for liver mass | ||
Axial T1 FS 3D GRE – Late Arterial | 16–20 s after injection | Assessment of arterial phase enhancement characteristics; assessment of hepatic artery. Note: For late arterial phase contrast should be present in the portal venous system, but not the hepatic veins |
Axial T1 FS 3D GRE – Portal Venous | 45–60 s after injection | Assessment of portal venous phase enhancement characteristics; assessment of portal vein |
Axial T1 FS 3D GRE – Delayed | 2–5 min after injection | Assessment of delayed phase enhancement characteristics; assessment of hepatic veins |
Coronal T1 FS 3D GRE – Delayed | Optional; 2–5 min after injection | Assessment of delayed phase enhancement characteristics; assessment of hepatic veins |
Biliary disease/MRCP
Quantitative parenchymal characterization
-
General: The presence of iron accelerates the decay of transverse magnetization in water protons, causing loss of signal in hepatic parenchyma in T2- and T2*-weighted imaging, which can be quantified by the transverse relaxation rates (T2 or T2*, seconds) or rates (R2 or R2*, 1/s).aTechnical considerations:i.FOV: Entire liverii.Field strength: 1.5T or 3T. Conversion to liver iron content requires different calibration equations based on field strength. 1.5 T may be preferred in patients with known or suspected severe iron overload [43].bR2* relaxometryi.Justification: To determine the relaxation rate R2* of the gradient echo signal, multiple gradient-echo images are typically acquired with increasing echo times within the same repetition time (TR). Reconstruction of the R2* maps includes a fitting of signal intensity decay to estimate the R2* relaxation rate, which is highly correlated and has a linear relationship with liver iron content (LIC). In 2023, a collaborative effort by the Society for Abdominal Radiology (SAR) and the European Society for Gastrointestinal and Abdominal Radiology (ESGAR) concluded that when available, confounder-corrected R2*-based LIC quantification is the most practical method with the strongest level of evidence for accurate and reproducible quantification of LIC [43].ii.Motion considerations: R2* mapping can be performed using parallel imaging to facilitate whole liver coverage in a single short breath-hold (8-12 seconds) while covering the whole liver volume in a 3D acquisition. Strategies for implementing the above sequences in a child who cannot hold their breath include increasing the signal averages and performing while free-breathing, reducing coverage to a single slice (reducing acquisition time to < 5 sec), and using respiratory navigation. New techniques utilizing 3D stack-of-stars radial acquisition [44] or multirepetition flip-angle modulated (FAM) acquisitions in combination with nonlocal means (NLM)-based motion-corrected averaging [45] show promise as free-breathing techniques for fat and iron quantification in children.iii.Pitfalls and Pearls/Tips and Tricks: In patients with severe iron overload, the hepatic parenchymal signal may decay too rapidly for standard msec GRE sequences. In these patients, shortening the initial TE to less than 1 msec can be helpful.iv.Post-processing: Conversion of R2* values to LIC requires field strength-specific calibration equations [46]. Although there are emerging automated segmented options, typically, regions of interest (ROIs) are drawn manually on the reconstructed R2* map to obtain R2* values. There is currently no consensus on how to draw ROIs. A common recommendation includes drawing at least 4 circular ROIs with a diameter of 2 cm or greater with at least 2 in the right lobe and at least 1 in the left lobe, avoiding areas of artifact, lesions, and vessels. The average R2* value of the 4 or more ROIs is used to estimate LIC. R2* and LIC values should be reported to the nearest integer [4].cR2 relaxometryi.Justification: An alternate relaxometry method for the quantification of iron is a spin-echoacquisition that uses a 90° radio frequency (RF) pulse followed by a 180° refocusing pulse and then samples the signal. The process is repeated with 5 sets of two-dimensional echo times to sample the signal decay due to the transverse relaxation and calculate the R2 relaxation rate.R2-based LIC quantification is available via the commercial products Ferriscan and Ferrismart (Resonance Health). These products are FDA-approved for LIC quantification and require an additional cost.ii.Motion considerations: Images are acquired over 10-20 minutes of free breathing.iii.Post-processing: For Ferriscan, acquired images are submitted electronically to Resonance Health’s data processing center for image processing, and an electronic report is returned with the mean R2 value and corresponding LIC value [47]. For Ferrismart, a cloud-based convolutional neural network trained on the database from FerriScan provides real-time analysis and instant LIC reporting [48].